Recent Advances in Copper Intercalators as Anticancer Agents
- PMID: 30171479
- DOI: 10.1007/s10895-018-2283-7
Recent Advances in Copper Intercalators as Anticancer Agents
Abstract
Copper is a part of various enzymes and helps them to function properly. It can be effectively used to produce promising anticancer drugs and presently, many studies are being pursued worldwide on the development of copper-based complexes as potential anticancer drugs. Herein, we briefly discuss the importance of reactive oxygen species in biological applications and copper(II) complexes as anticancer drugs. The anti-angiogenic properties of mono-nuclear copper(II) complexes have been demonstrated by in vivo chick embryo angiogenesis analysis. The plausible mechanism behind anticancer activity of these complexes is by the formation of excessive intracellular Reactive Oxygen Species (ROS). ROS is a composite term used for oxygen derivative non-radicals and free radicals of highly reactive components, that enhances the killing response of immune cells to microbial invasion. Previous reports have shown that ROS plays an important role as a messenger in cell cycling and normal cell signal transduction. Graphical Abstract The generation of singlet oxygen and healing the tumor cells with singlet oxygen in presence of UV-light.
Keywords: Angiogenesis; Cancer; Copper; DNA; ROS.
Similar articles
-
Synthesis of four binuclear copper(II) complexes: Structure, anticancer properties and anticancer mechanism.Eur J Med Chem. 2015;96:360-8. doi: 10.1016/j.ejmech.2015.04.031. Epub 2015 Apr 14. Eur J Med Chem. 2015. PMID: 25899339
-
Four copper(II) compounds synthesized by anion regulation: Structure, anticancer function and anticancer mechanism.Eur J Med Chem. 2016 Oct 4;121:399-409. doi: 10.1016/j.ejmech.2016.05.021. Epub 2016 May 14. Eur J Med Chem. 2016. PMID: 27309677
-
Self-activating nuclease and anticancer activities of copper(II) complexes with aryl-modified 2,6-di(thiazol-2-yl)pyridine.Dalton Trans. 2013 Aug 28;42(32):11576-88. doi: 10.1039/c3dt50395j. Epub 2013 Jul 10. Dalton Trans. 2013. PMID: 23843095
-
Copper complexes as anticancer agents.Anticancer Agents Med Chem. 2009 Feb;9(2):185-211. doi: 10.2174/187152009787313837. Anticancer Agents Med Chem. 2009. PMID: 19199864 Review.
-
Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors.Anticancer Agents Med Chem. 2017;17(8):1046-1069. doi: 10.2174/1871520617666170213150217. Anticancer Agents Med Chem. 2017. PMID: 28270080 Review.
Cited by
-
Enhanced antitumor effect of L-buthionine sulfoximine or ionizing radiation by copper complexes with 2,2´-biquinoline and sulfonamides on A549 2D and 3D lung cancer cell models.J Biol Inorg Chem. 2022 Apr;27(3):329-343. doi: 10.1007/s00775-022-01933-8. Epub 2022 Mar 5. J Biol Inorg Chem. 2022. PMID: 35247094
-
Synthesis, characterization, molecular docking studies, and theoretical calculations of novel Ni (II), Cu (II), and Zn (II) complexes based on benzothiazole derivative.BMC Chem. 2025 Jul 4;19(1):202. doi: 10.1186/s13065-025-01576-1. BMC Chem. 2025. PMID: 40616156 Free PMC article.
-
A Novel Copper(II) Indenoisoquinoline Complex Inhibits Topoisomerase I, Induces G2 Phase Arrest, and Autophagy in Three Adenocarcinomas.Front Oncol. 2022 Feb 24;12:837373. doi: 10.3389/fonc.2022.837373. eCollection 2022. Front Oncol. 2022. PMID: 35280788 Free PMC article.
-
Synthesis and Biological Activity of a New Indenoisoquinoline Copper Derivative as a Topoisomerase I Inhibitor.Int J Mol Sci. 2023 Sep 26;24(19):14590. doi: 10.3390/ijms241914590. Int J Mol Sci. 2023. PMID: 37834037 Free PMC article.
-
Synthesis, Structure, and Stability of Copper(II) Complexes Containing Imidazoline-Phthalazine Ligands with Potential Anticancer Activity.Pharmaceuticals (Basel). 2025 Mar 6;18(3):375. doi: 10.3390/ph18030375. Pharmaceuticals (Basel). 2025. PMID: 40143151 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources